arrow
B

Bahriye Aktas

medical center
H指数:42
被引数:8,707

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Microsatellite Instability Status and Mismatch Repair Defects Testing in Endometrial Cancer—Insights from the Multicenter E-PEC Trial

微卫星不稳定性状态与错配修复缺陷检测在子宫内膜癌中的应用——来自多中心E-PEC试验的见解

2026-03-040
OAAI
Experiences and Expectations of Advance Directives in Gynecological Cancer Patients (The NOGGO-Expression X Study)

妇科癌症患者关于预立医疗指示的经历与期望(NOGGO-Expression X研究)

2025-07-190
OAAI
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial

在内分泌治疗 upfront letrozole 的基础上接受新辅助/辅助化疗的绝经后激素受体阳性、HER2阴性早期乳腺癌患者中,其浸润性肿瘤无复发生存和总生存情况:基于IV期PreFace试验的经验

2025-07-110
OA
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk

绝经前早期激素受体阳性、HER2阴性且复发风险增加的乳腺癌患者中,芳香化酶抑制剂、他莫昔芬和卵巢功能抑制的实际情况应用。

BREAST
IF7.9
2025-06-010
OAAI
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

早期三阴性乳腺癌经新辅助紫杉烷类药物治疗后的TNBC-DX基因组检测

2025-02-014
OAAI
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/ HER2neg breast cancer patients treated with upfront letrozole
2024-09-012
OAAI
HER2DX genomic assay in triple-negative breast cancer (TNBC) patients treated with 12-weeks of neoadjuvant chemotherapy: a correlative analysis from WSGADAPT-TN phase II trial
2024-05-020
PRE